Cytoplasmic IgM in leukemic B cells by flow cytometry.

Abstract:

:The presence of intracellular cytoplasmic immunoglobulin M (IgM) in leukemic cells from patients with acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL) was investigated by flow cytometry. The objective of the study was to develop a reproducible flow cytometric method. A Burkitt's lymphoma-derived B-cell line, Daudi, and a pre-B ALL, Nalm-6, served as prototypes. Normal B cells and cells from patients with chronic myelogenous leukemia (CML) were used as negative controls. Cytoplasmic mu was expressed in 77.3 +/- 7.5% (n = 10) of Nalm-6 cells. CALLA+ ALL and CML cells lacked cytoplasmic mu. The surface-membrane immunoglobulin on the viable B cells was blocked with purified goat anti-human IgM. Subsequently, the B cells were fixed in cold absolute methanol and stained with a fluorescein-conjugated goat anti-human IgM to demonstrate cytoplasmic IgM. After the surface-membrane IgM was blocked, normal B cells had no cytoplasmic IgM (0.3-0.5% positive cells) detectable by flow cytometry. However, the peripheral blood lymphocytes from five patients with CLL and the Daudi cells contained cytoplasmic IgM, ranging from 7.8 to 76.7% and 45.7 to 89.3%, respectively. We conclude that cytoplasmic mu in Nalm-6, CLL, and Daudi cells can be easily and rapidly demonstrated by flow cytometry.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Loftin KC,Reuben JM,Hersh EM,Sujansky D

doi

10.1016/0145-2126(85)90126-2

subject

Has Abstract

pub_date

1985-01-01 00:00:00

pages

1379-87

issue

11

eissn

0145-2126

issn

1873-5835

pii

0145-2126(85)90126-2

journal_volume

9

pub_type

杂志文章
  • Properties of lymphocyte 5'nucleotidase in normal subjects and patients with chronic lymphocytic leukemia.

    abstract::Heterogeneity for 5'nucleotidase has been demonstrated in chronic lymphocytic leukemia [12]. The enzyme is not detectable in the lymphocytes from the majority of patients with this disorder, but normal and even supranormal levels are found in some cases [17]. In the present studies, the properties of this ecto-nucleot...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(82)90026-1

    authors: Conklyn MJ,Silber R

    更新日期:1982-01-01 00:00:00

  • Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.

    abstract::Secondary acute lymphoblastic leukemia (s-ALL) is rare and poorly defined and data regarding outcomes post-transplant are lacking. Here, we report a detailed analysis of s-ALL at our Institution. Among 211 eligible patients with ALL from 2006 to 2017, 30 (14%) were defined as s-ALL and the remaining as primary ALL (p-...

    journal_title:Leukemia research

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.leukres.2018.07.024

    authors: Ferraro F,Gao F,Stockerl-Goldstein K,Westervelt P,DiPersio JF,Ghobadi A

    更新日期:2018-09-01 00:00:00

  • Sustained disease control in transplant-ineligible patients: the role of continuous therapy.

    abstract::Many patients with multiple myeloma (MM) are elderly (aged >65 years) or unfit, and therefore ineligible for stem-cell transplantation. The novel agents thalidomide, bortezomib, and lenalidomide have shown improved outcomes in these patients. This article discusses the role of continuous therapy in improving patient o...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/S0145-2126(12)70005-X

    authors: Palumbo A,Niesvizky R

    更新日期:2012-11-01 00:00:00

  • Myelodysplastic syndromes in patients under 50 years old: a single institution experience.

    abstract::We report on our experience relating to 62 patients with myelodysplastic syndrome (MDS) aged less than 50 years, seen at our Institution and conservatively treated from July 1983 to December 2000. Patients demographics and clinical features at diagnosis were analysed for their prognostic value on survival and on risk ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.01.003

    authors: Breccia M,Mengarelli A,Mancini M,Biondo F,Gentilini F,Latagliata R,Mandelli F,Alimena G

    更新日期:2005-07-01 00:00:00

  • Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia.

    abstract::We examined polymorphisms of glutathione S-transferase (GST) genes in 159 Japanese patients with myelodysplasia and compared the incidence with that in 43 normal individuals to clarify their pathogenetic significance in myelodysplasia. In individuals with the GSTT1 null genotype, the odds ratios for disease risk were ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(99)00119-8

    authors: Sasai Y,Horiike S,Misawa S,Kaneko H,Kobayashi M,Fujii H,Kashima K,Taniwaki M

    更新日期:1999-11-01 00:00:00

  • CD14 mediated endogenous TNF-alpha release in HL60 AML cells: a potential model for CD14 mediated endogenous cytokine release in the treatment of AML.

    abstract::In previous studies, HL60 AML cells treated with tumor necrosis factor-alpha (TNF), interferon-gamma (IFN), and lipopolysaccharides (LPS) displayed decreased growth and viability, enhanced monocytic pathway differentiation and endogenous TNF release. Endogenous TNF release by LPS/TNF/IFN treated HL60 cells was postula...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(94)90004-3

    authors: Treon SP,Anand B,Ulevitch R,Broitman SA

    更新日期:1994-01-01 00:00:00

  • Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.

    abstract::Acute myeloid leukemia (AML) is a heterogeneous disease. Until recently, treatment for patients with AML was limited to induction chemotherapy with cytarabine and anthracycline or hypomethylating agents, and, in some instances, allogeneic hematopoietic stem cell transplant. With the recent approval of new therapies-i....

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2018.09.001

    authors: Talati C,Sweet K

    更新日期:2018-10-01 00:00:00

  • Lineage relationship of chronic lymphocytic leukemia and hairy cell leukemia: studies with TPA.

    abstract::The tumor promoting agent TPA (phorbol ester; 1.6 X 10(-8)M) was used to induce the differentiation in vitro of B-chronic lymphocytic leukemia (B-CLL) cells from 14 untreated patients. The uninduced phenotype was SIg+, Mrbc+, RFT-1+, RFA-4-, FMC7-. After 72 h incubation with TPA, B-CLL cells became RFA-4+, FMC7+ and l...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(84)90005-5

    authors: Caligaris-Cappio F,Janossy G,Campana D,Chilosi M,Bergui L,Foà R,Delia D,Giubellino MC,Preda P,Gobbi M

    更新日期:1984-01-01 00:00:00

  • Cancer chemotherapy reduces plasma total antioxidant capacity in children with malignancies.

    abstract::The sum of endogenous and food-derived antioxidants provides an estimate of the total antioxidant capacity (TAC) of the extracellular fluids, while corrected TAC (cTAC) is an estimation of the exogenously provided antioxidants. Similar values for TAC and cTAC were observed between cancer free children and children wit...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.04.017

    authors: Papageorgiou M,Stiakaki E,Dimitriou H,Malliaraki N,Notas G,Castanas E,Kalmanti M

    更新日期:2005-01-01 00:00:00

  • Analysis of T-cell receptor-γ gene rearrangements using heteroduplex analysis by high-resolution microcapillary electrophoresis.

    abstract::Determination of T-cell clonality has an important additional value for diagnosis of T-cell lymphomas. Various molecular methods have been developed, including polymerase chain reaction (PCR) of T-cell receptor γ (TCRγ). The detection of PCR products usually relies commonly on either GeneScan (GS) analysis or heterodu...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.06.003

    authors: Beaufils N,Ben Lassoued A,Essaydi A,Dales JP,Formisano-Tréziny C,Bonnet N,Grob JJ,Gabert J

    更新日期:2012-09-01 00:00:00

  • Near-tetraploid poorly differentiated acute myeloid leukemia M0 diagnosed by short-term cultures with a phorbol ester TPA.

    abstract::Leukemic blasts of two patients with acute leukemia exhibited similar characteristics. They were heterogeneous in size with a diameter of 14-30 microns in smears and unclassifiable by morphological, cytochemical, immunophenotypic and ultrastructural examinations. Cytogenetic examinations of both revealed a near-tetrap...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(94)90087-6

    authors: Lemez P,Jelínek J,Michalová K,Koubek K,Schwarz J,Malasková V,Rypácková B,Jirásek A,Brezinová J,Hrabánek J

    更新日期:1994-07-01 00:00:00

  • Nilotinib post-liver transplantation for acute hepatic failure related to imatinib.

    abstract::This is the case report of a 47-year-old woman referred to our institution due to acute liver failure related to imatinib, who was submitted to a successful liver transplantation. Nilotinib was safely used post-transplant. ...

    journal_title:Leukemia research

    pub_type: 信件

    doi:10.1016/j.leukres.2009.06.012

    authors: Perini GF,Santos FP,Funke V,Ruiz J,Neto BH,Hamerschlak N

    更新日期:2009-12-01 00:00:00

  • Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy.

    abstract::We investigated protracted low-dose oral Clofarabine for the treatment of myelodysplastic syndromes (MDS). Adults with an International Prognostic Scoring System (IPSS) score of INT-1 or higher who had failed first line therapy were eligible. INT-1 patients had to be transfusion-dependent. We started with oral Clofara...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.05.004

    authors: Rudrapatna VK,Morley K,Boucher KM,Pierson AS,Shull CT,Kushner JP,Shami PJ

    更新日期:2015-08-01 00:00:00

  • Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib.

    abstract::MicroRNA (miRNA) is an important regulator of cellular proliferation, differentiation and death. Leukemia-specific signature of miRNAs suggests that epigenetic dysregulation of miRNAs is important for leukemogenesis. We focused on the role of DNA methylation of miR-203 which targets BCR-ABL1 mRNA. The microarray analy...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2013.07.019

    authors: Shibuta T,Honda E,Shiotsu H,Tanaka Y,Vellasamy S,Shiratsuchi M,Umemura T

    更新日期:2013-10-01 00:00:00

  • Hyaluronan induces migration of multidrug-resistant lymphoma cell lines in vitro through Tiam1 activation by a PI3K-dependent mechanism.

    abstract::Hyaluronan (HA) modulates multidrug resistance (MDR) as well as cell migration. Tiam1 is involved in cytoskeleton reorganization during tumor invasion. In this report we show the relationship among HA, Tiam1, migration and MDR in murine lymphoma cell lines. We observed that MDR cells presented higher migratory capacit...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2010.02.020

    authors: Cordo-Russo RI,Alaniz LD,Saccodossi N,Lompardía S,Blanco G,Alvarez E,García MG,Hajos SE

    更新日期:2010-11-01 00:00:00

  • Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.

    abstract::This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6%) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1% for palpitations, 4.3% for angina, 3.5% for arterial hypertension, 3.0% fo...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2011.06.030

    authors: Gugliotta L,Tieghi A,Tortorella G,Scalzulli PR,Ciancia R,Lunghi M,Cacciola E,Cacciola R,Candoni A,Crugnola M,Codeluppi K,Usala E,Specchia G,Martinelli V,Palmieri F,Pierri I,Liberati AM,Iurlo A,Grossi A,Vannucchi AM

    更新日期:2011-12-01 00:00:00

  • Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.

    abstract:BACKGROUND:T- cell prolymphocytic leukemia (T- PLL) is a rare aggressive hematological malignancy. Alemtuzumab, an anti-CD52 humanized monoclonal antibody, is the treatment of choice for remission induction. Allogeneic hematopoietic cell transplantation (allo-HCT) has been described to induce durable remissions and imp...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2018.01.009

    authors: Dholaria BR,Ayala E,Sokol L,Nishihori T,Chavez JC,Hussaini M,Kumar A,Kharfan-Dabaja MA

    更新日期:2018-04-01 00:00:00

  • Constitutional trisomy 8 and myelodysplasia: report of a case and review of the literature.

    abstract::A diagnosis of myelodysplastic syndrome was made in an 18-year-old patient with Warkany syndrome due to constitutional trisomy 8 mosaicism. The possible causal role of this particular chromosome constitution with respect to myelodysplasia and embryonal childhood tumors is discussed. ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(95)00050-x

    authors: Zollino M,Genuardi M,Bajer J,Tornesello A,Mastrangelo S,Zampino G,Mastrangelo R,Neri G

    更新日期:1995-10-01 00:00:00

  • Relationship between cyclin D1 and p21(Waf1/Cip1) during differentiation of human myeloid leukemia cell lines.

    abstract::Expression of cell cycle-regulating genes was studied in human myeloid leukemia cell lines ML-1, ML-2 and ML-3 during induction of differentiation in vitro. Myelomonocytic differentiation was induced by phorbol ester (12-o-Tetradecanoyl-phorbol-13-acetate, TPA), tumor necrosis factor alpha (TNFalpha) or interferon gam...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(03)00103-6

    authors: Ullmannová V,Stöckbauer P,Hradcová M,Soucek J,Haskovec C

    更新日期:2003-12-01 00:00:00

  • Levels of CAF7 (CD98) expression correlate with the complete remission duration in childhood acute leukemia.

    abstract::The levels of expression of the activation antigen CD98 were studied by mAB CAF7 in 51 newly diagnosed consecutive cases of childhood acute lymphoblastic leukemia aged from 1 to 13 years. The mean follow-up was 8 months. A wide range of CAF7 expression was observed, the highest mean fluorescence intensity exceeding th...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(95)00114-x

    authors: Taskov H,Pashov A,ffmitrova E,Yordanova M,Serbinova M

    更新日期:1996-01-01 00:00:00

  • Clonality analysis of childhood ALL in remission: no evidence of clonal hematopoiesis.

    abstract::We studied 98 female patients in remission (2-240 months) from childhood ALL to determine the clonality status of their hematopoiesis. Thirty-one (31.6%) were heterozygous at the PGK locus for the BstX1 endonuclease restriction site, permitting X-linked clonality assays to be performed. Two patients were in relapse at...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(94)90121-x

    authors: Busque L,Ilaria R Jr,Tantravahi R,Weinstein H,Gilliland DG

    更新日期:1994-02-01 00:00:00

  • Real-world costs of chronic lymphocytic leukaemia in the Netherlands.

    abstract::We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) recei...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2013.10.029

    authors: Holtzer-Goor KM,Bouwmans-Frijters CA,Schaafsma MR,de Weerdt O,Joosten P,Posthuma EF,Wittebol S,Huijgens PC,Mattijssen EJ,Vreugdenhil G,Visser H,Peters WG,Erjavec Z,Wijermans PW,Daenen SM,van der Hem KG,van Oers MH,Groot

    更新日期:2014-01-01 00:00:00

  • Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

    abstract::Peripheral neuropathy (PN), with neuropathic pain as main symptom, represents the dose-limiting toxicity of the proteasome inhibitor bortezomib. Aim of this study was to compare the incidence, risk factors, severity and outcome of PN and neuropathic pain in patient treated with bortezomib up-front or at relapse. We st...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.07.022

    authors: Corso A,Mangiacavalli S,Varettoni M,Pascutto C,Zappasodi P,Lazzarino M

    更新日期:2010-04-01 00:00:00

  • Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.

    abstract::Treatment of CMML remains a clinical challenge, with no drug demonstrating clear clinical benefit. Even if azacitidine is approved in the treatment of CMML, its role remains disputed. We report a cohort of 76 CMML patients (according to WHO classification) treated with azacitidine in 3 programs (French AZA compassiona...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2013.01.004

    authors: Adès L,Sekeres MA,Wolfromm A,Teichman ML,Tiu RV,Itzykson R,Maciejewski JP,Dreyfus F,List AF,Fenaux P,Komrokji RS

    更新日期:2013-06-01 00:00:00

  • Semenogelin I expression in myeloma cells can be upregulated pharmacologically.

    abstract::Semenogelin (SEMG) I is a Cancer-Testis (CT) antigen that we have found to be expressed in myeloma cells. In this study, we set out to determine whether the expression of SEMG I could be upregulated pharmacologically. We found that SEMG I expression in myeloma cells can be upregulated by 5-azacytidine, IL-4 and IL-6. ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.03.036

    authors: Zhang Y,Wang Z,Zhang J,Farmer B,Lim SH

    更新日期:2008-12-01 00:00:00

  • Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias.

    abstract::Over-expression of the Flt3 is prevalent in acute myeloblastic leukemia (AML), playing a role in leukemogenesis while decreased expression of PU.1 induces AML in mice model. Therefore, we speculated that there is an inverse relationship between these two factors. To clarify this, we measured the expression level of Fl...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.07.015

    authors: Inomata M,Takahashi S,Harigae H,Kameoka J,Kaku M,Sasaki T

    更新日期:2006-06-01 00:00:00

  • Genotypic and cytogenetic study of acute myelocytic leukemia and chronic myelocytic leukemia in blast crisis: specific delta rearrangement pattern does not involve J delta gene locus.

    abstract::We have analysed the configuration of immunoassociated genes and the karyotypes of 30 patients with acute myelocytic leukemia (AML) and 10 with chronic myelocytic leukemia in blast crisis (CML-BC). In AML, the frequencies of T-cell receptor (TcR) beta, gamma, and delta chain and immunoglobulin heavy and light chain ge...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(91)90070-a

    authors: Akiyoshi TT,Kimura N,Uike N,Kozuru M,Tamura K,Takihara Y,Hisano S,Nishimura J,Kikuchi M

    更新日期:1991-01-01 00:00:00

  • Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice.

    abstract::A novel bivalent single chain fusion protein, Bic3, was assembled consisting of the catalytic and translocation domains of diphtheria toxin (DT(390)) fused to two repeating sFv molecules recognizing human CD3 epsilon of the human T-cell receptor. Historically, problems with these constructs include low yield, toxicity...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.08.006

    authors: Vallera DA,Todhunter D,Kuroki DW,Shu Y,Sicheneder A,Panoskaltsis-Mortari A,Vallera VD,Chen H

    更新日期:2005-03-01 00:00:00

  • Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.

    abstract::5-Aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation and an active antileukemic agent, produced an induction of cytidine deaminase activity in human HL-60 myeloid leukemic cells. This increase in enzyme activity correlated with the induction of differentiation of the HL-60 leukemic cells as shown ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(90)90067-j

    authors: Momparler RL,Laliberté J

    更新日期:1990-01-01 00:00:00

  • Myelodysplastic syndrome associated with Griscelli syndrome.

    abstract::Myelodysplastic syndrome (MDS) in children has been reported to be associated with various constitutional anomalies; however, it has not been described previously in patients with Griscelli syndrome (GS). In this report, we present a case with GS and refractory anemia with an excess of blasts. We believe that careful ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(98)00075-7

    authors: Cetin M,Hiçsönmez G,Göğüş S

    更新日期:1998-09-01 00:00:00